← The Wire
RLMDNasdaq
RELMADA THERAPEUTICS, INC.
Pharmaceutical Preparations · NV · CIK 1553643
Relmada Therapeutics develops novel drug formulations for bladder cancer and neurological disorders
$698M
Market cap
$6.98
Last close
+4.3%
1D
+1.3%
5D
2.3M
Volume
Price · last 39 sessions-5.8%
May 4L $5.72 · H $7.86Jun 29
272
Total filings
May 28, 2026
Last filing
12/31
Fiscal year end
DEF 14APROXY STATEMENTApr 17, 2026DEF 14APROXY STATEMENTApr 11, 2025DEF 14APROXY STATEMENTApr 9, 2024DEF 14APROXY STATEMENTMar 31, 2023DEF 14APROXY STATEMENTApr 11, 2022DEF 14ADEFINITIVE PROXY STATEMENTMar 31, 2021DEF 14ADEFINITIVE PROXY STATEMENTJan 31, 2020DEF 14ADEFINITIVE PROXY STATEMENTJan 9, 2019DEF 14ADEFINITIVE PROXY STATEMENTDec 15, 2017DEF 14ADEFINITIVE PROXY STATEMENTDec 30, 2016DEF 14ADEFINITIVE PROXY STATEMENTNov 27, 2015DEF 14ADEFINITIVE PROXY STATEMENTSNov 17, 2014
Insider Activity
◆ Cluster Buy · 4 insidersIn the 90 days to Dec 15, 2025: 4 insiders bought $2.4M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 15, 2025 | Traversa SergioChief Executive Officer | Buy | 27,500 | $4.12 | $113K |
| Dec 15, 2025 | Shenouda MagedChief Financial Officer | Buy | 11,665 | $4.12 | $48K |
| Nov 5, 2025 | Shenouda MagedChief Financial Officer | Buy | 500,000 | $2.20 | $1.1M |
| Nov 5, 2025 | Traversa SergioChief Executive Officer | Buy | 272,500 | $2.20 | $600K |
| Nov 5, 2025 | Ence ChuckCAO and COO | Buy | 136,000 | $2.20 | $299K |
| Nov 5, 2025 | Kelly Paul EdwardChief Operating Officer | Buy | 90,000 | $2.20 | $198K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance